JUN 1 8 2004

PTO/SB/08A (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE (eduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO 10/788,606 Application Number Filing Date February 27, 2004 INFORMATION DISCLOSURE First Named Inventor Mary E. Brunkow 1644 STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessary) **Examiner Name** 60117-109 Attorney Docket Number Sheet

			U.S. PATENT DO		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (if known)}			Figures Appear
X3		US-5,837,458	11-17-1998		
XZ		US-5,830,721	11-03-1998		
XZ		US-5,811,238	09-22-1998		
XZ		US-5,780,263	07-14-1998		
XZ		US-5,453,492	09-26-1995		
XZ		US-4,376,110	03-08-1983		
		US-			
		US-		•	
		US-	ļ		
		US-		***************************************	·
		US-			
	<u> </u>	US-			
	ļ	US-			
		US-			
		US-		•	1

Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	. т
Initiats*	No.'	Country Code 3-Number 4-Kind Code 5 (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Or Relevant Figures Appear	
XZ		WO-92/06693	04-30-1992			_
XZ		WO-91/13152	09-05-1991			├-
					·	╁
						T
						T

Examiner Signature	Zinda Zi	Date Considered	8/22/2005
Signature	market in the second	Considered	9/00/000

"EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Su	bstitute for form 144	9/PTO			Complete if Known	
INEO	RMATION	DIS	CI OSHBE	Application Number	10/788,606	
	TEMENT B			Filing Date	February 27, 2004	
• • • • • • • • • • • • • • • • • • • •				First Named Inventor	Mary E. Brunkow	
	(Use as many she	et s as n	ecessary)	Art Unit	1644	
				Examiner Name		
Sheet	2	of	2	Attorney Docket Number	60117-109	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials•	No.1.	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
XZ		BONALDO ET AL., Accession No. A/113131, EMBL SEQUENCE DATABASE, 1998.	
XZ		HSU ET AL., The Xenopus Dorsalizing Factor Gremlin Indentifies a Novel Family of Secreted Proteins that Antagonize BMP Activities, MOLECULAR CELL, 1:673-683, 1998.	
χZ		IEMURA ET AL., Direct Binding of Follistatin to a Complex of Bone-Morphogenetic Protein and its Receptor Inhibits Ventral and Epidermal Cell Fates in Early Xenopus Embryo, PROC. NATL. ACAD. SCI. USA, 95:9337-9342, 1998.	
XS		BIRREN ET AL., Accession No. AC003098, EMBL SEQUENCE DATABASE, 1997.	
χŽ		HILLER ET AL., Accession No. AA393939, EMBL SEQUENCE DATABASE, 1997.	
XZ		HILLER ET AL., Accession No. AA393768, EMBL SEQUENCE DATABASE, 1997.	
XZ		BONALDO ET AL., Normalization and Subtraction: Two Approaches to Facilitate Gene Discovery, GENOME RES., 6(9):791, 1996.	
45		FUJIWARA ET AL., Accession No. D79813, EMBL SEQUENCE DATABASE, 1996.	
χZ	·	KHOSLA ET AL., Concise Review for Primary-Care Physicians. Treatment Options for Osteoporosis, MAYO CLIN PRO, 70:978-982, 1995.	
χZ		HAY ET AL., ATCC CELL LINES AND HYBRIDOMAS, 8TH ED., 149, 258 AND 428, 1994.	
χZ		RIGGS, Overview of Osteoporosis, WEST J. MED., 154:63-77, 1991.	
χZ		HARLOW ET AL., ANTIBODIES: A LABORATORY MANUAL, COLD SPRING HARBOR LABORATORY, COLD SPRING HARBOR, NY, 141-157, 1988.	

Examiner	212	Date	8/22/2005
Signature	lever di	Considered	0/22/2005

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (05-03)

Approved for use through 04/30/2003, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paper of Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Coppigned om 1449/PTO	· Co	mplete if Known
·	Application Number	10/788,606
INFORMATION DISCLOSURE	Filing Date	February 27, 2004
INFORMATION DISCLOSURE	First Named Inventor	Mary E. Brunkow
STATEMENT BY APPLICANT	Art Unit	1644
(Use as many sheets as necessary)	Examiner Name	Patrick Nolan
Sheet 1 of 4	Attorney Docket Number	60117-109

				DOCUMENTS	
Examiner Initials*	Cite No. 1	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
	140.	Number-Kind Code ^{2 (d known)}	MM-DD-YYYY	Applicant of ones bocoment	Figures Appear
XZ	AA	6,395,511	05-28-2002	Brunkow et al.	
	AB				
	AC				
	AD				
	AE	•			
	AF				
	AG			·	
	АН				
	Al				
	AJ.				
	AK				
	AL				
	АМ				
	AN				
	AO			·	
	AP				

		FORE	IGN PATENT DOCU	MENTS		
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	Τ.
Initials*	No.'	Country Code 3-Number 4-Kind Code 5 (# known)	Date MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Retevant Passages Or Relevant Figures Appear	Ľ
X3	AQ	WO 02/24888 A2	03-28-2002	GENENTECH, INC.		
	AR	<u> </u>				
	AS					
	AT					
	AU					
	AV					Γ

Examiner Signature	Zoch Zi	Date Considered	8/22/2005

*EXAMINER: Initial if reference copardared, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995,no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Su	obstitute for form 144	9/PTO			Complete if Known
INEO	RMATION	חופו	CLOSURE	Application Number	10/788.606
	TEMENT B			Filing Date	February 27, 2004
				First Named Inventor	Mary E. Brunkow
	(Use as many she	ets as n	ecessary)	Art Unit	1644
				Examiner Name	Patrick Nolan
Sheet	2	of	4	Attorney Docket Number	60117-109

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
XZ	ВА	Genbank Accession No. AAB33865, May 27, 1995.	
X٤	ВВ	Genbank Accession No. CAA88759, January 8, 1997.	
хг	ВС	Genbank Accession No. U25110, February 2, 1996.	
хг	BD	Genbank Accession No. Z48923, January 8, 1997.	
χZ	BE	BENDAYAN, M., "Possibilities of False Immunocytochemical Results Generated by the Use of Monoclonal Antibodies: The Example of the Anti-proinsulin Antibody," J. Histochem. Cytochem. (1995) 43(9): 881-886.	
X2	BF	BOST ET AL., "Antibodies Against a Peptide Sequence within the HIV Envelope Protein Crossreacts with Human Interleukin-2," Immunol. Invest. (1988) 17(6&7):577-586.	
XZ	ВG	BRUNKOW ET AL., "Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cysteine Knot-Containing Protein." Am. J. Hum. Genet. (2001) 68:577-589.	
XZ	вн	CAMPBELL ET AL., "Totipotency or Multipotentiality of Cultured Cells: Applications and Progress," Theriogenology (1997) 47:63-72.	
χZ	ВІ .	COLMAN, P., "Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions," Research in Immunology (1994) 145:33-36.	

	21		
Examiner Signature	200	Date	8/22/005
Signature	m gover	_ Considered	0100/3003

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08B (05-03)
Approved for use through 04/30/2003, OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995,no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INIEC		DIG	CI OSLIDE	Application Number	10/788.606
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	February 27, 2004
• • • • • • • • • • • • • • • • • • •				First Named Inventor	Mary E. Brunkow
	(Use as many she	ets as n	ecessary)	Art Unit	1644
				Examiner Name	Patrick Nolan
Sheet	3	of	4	Attorney Docket Number	60117-109

	_	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
XZ	CA	DURHAM ET AL., "Alterations in Insulin-Like Growth Factor (IGF)-Dependent IGF-Binding Protein-4 Proteolysis in Transformed Osteoblastic Cells" Endocrinology (1995) 136(4):1374-1380.	
X3	СВ	HOFFMAN ET AL., "BMP Signaling Pathways in Cartilage and Bone Formation," Critical Review in Eukaryotic Gene Expression (2001) 11(1-3):23-45.	
ΧS	СС	LIAN ET AL., "Bone Formation: Osteoblast Lineage Cells, Growth Factors, Matrix Proteins, and the Mineralization Process," Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 4 th Edition (1999) 14-29.	
XZ	CD	MULLINS ET AL., "Perspectives Series: Molecular Medicine in Genetically Engineered Animals; Transgenesis in the Rat and Larger Mammals," J. Clin. Invest. (1996) 97(7):1557-1560	
χZ	CE	NICOLAS ET AL., "An Age-Related Decrease in the Concentration of Insulin-Like Growth Factor Binding Protein-5 in Human Cortical Bone," Calcif. Tissue Int. (1995) 57:206-212	
XZ	CF	OSHIMA ET AL., "TGF-& Receptor Type II Deficiency Results in Defects of Yolk Sac Hematopoiesis and Vasculogenesis," Developmental Biology (1996) 179:297-302.	
X5	CG	PITTENGER ET AL., "Multilineage Potential of Adult Human Mesenchymal Stem Cells," Science (1999) 284:143-147.	
XZ	СН	POCKWINSE ET AL., "Expression of Cell Growth and Bone Specific Genes at Single Cell Resolution During Development of Bone Tissue-Like Organization in Primary Osteoblast Cultures," Journal of Cellular Biochemistry (1992) 49:310-323.	
XZ	CI	SALI ET AL., "Comparative Protein Modelling by Satisfaction of Spatial Restraints," J. Mol. Biol. (1993) 234:779-815.	

Examiner . Signature	Kirgh Li	Date Considered	8/20/2005

PTO/SB/08B (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995,no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE				Application Number	10/788.606
STATEMENT BY APPLICANT				Filing Date	February 27, 2004
• • • • • • • • • • • • • • • • • • •	(Use as many sheets as necessary)			First Named Inventor	Mary E. Brunkow
				Art Unit	1644
		Examiner Name	Patrick Nolan		
Sheet	4	of	4	Attorney Docket Number	60117-109

-		NON DATENT LITEDATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
χž	DA	SCHMITT ET AL., "Bone Morphogenetic Proteins: An Update on Basic Biology and Clinical Relevance," Journal of Orthopaedic Research (1999) 17:269-278.	
χž	DB	SCHLUNEGGER ET AL., "Refined Crystal Structure of Human Transforming Growth Factor ß2 at 1.95 Å Resolution," J. Mol. Biol. (1993) 231:445-458.	
ΧZ	DC	SERRA ET AL., "Expression of a Truncated, Kinase-Defective TGF-B Type II Receptor in Mouse Skeletal Tissue Promotes Terminal Chondrocyte Differentiation and Osteoarthritis," J Cell Biol. (1997) 139(2):541-552.	
*5	DD	SMITH, "TGF ß Inhibitors, New and Unexpected Requirements in Vertebrate Development," TIG (1999) 15(1):3-5.	
ΧZ	DE	ZIMMERMAN ET AL., "The Spemann Organizer Signal noggin Binds and Inactives Bone Morphogenetic Protein 4," Cell (1996) 86:599-606.	
	DG		•
	DH		
	DI		

Examiner Signature	Tengh Zi	Date Considered	8/22/2005